CMS Posts Final Payment Determination for bioAffinity Technologies CyPath Lung Effective January 2024

SAN ANTONIO - bioAffinity Technologies, Inc. , a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the...

Related Keywords

United States ,American ,Julie Anne Overton ,Maria Zannes ,While The Company ,University Of Texas At San Antonio ,Centers For Medicare ,Medicare Clinical Lab Fee Schedule ,Affinity Technologies Inc ,Company Annual Report On Form ,American Medical Association ,Medicare Advisory Panel On Clinical Diagnostic Laboratory ,Medicare Advisory Panel ,Laboratory Developed Test ,Medicaid Services ,Precision Pathology Laboratory Services ,Nasdaq ,Laboratory Analyses ,Affinity Technologies ,Cypath Lung ,Affinity Technologies President ,Advisory Panel ,Clinical Diagnostic Laboratory Tests ,Current Procedural Terminology ,Clinical Lab Fee Schedule ,Medical Association ,Path Lung ,Annual Report ,News Publishing ,Markets ,